|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0021149,
umls-concept:C0026565,
umls-concept:C0033572,
umls-concept:C0038954,
umls-concept:C0040833,
umls-concept:C0205549,
umls-concept:C0220908,
umls-concept:C0332120,
umls-concept:C0332185,
umls-concept:C0376358,
umls-concept:C0733511,
umls-concept:C1280500,
umls-concept:C1521798
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1999-6-29
|
|
pubmed:abstractText |
The prostate-specific antigen test was approved by the U.S. Food and Drug Administration in 1986 to monitor the disease status in patients with prostate cancer and, in 1994, to aid in prostate cancer detection. However, after 1986, the test was performed on many men who had not been previously diagnosed with prostate cancer, apparently resulting in the diagnosis of a substantial number of early tumors. Our purpose is to provide insight into the effect of screening on prostate cancer rates. Detailed data are presented for whites because the size of the population allows for calculating statistically reliable rates; however, similar overall trends are seen for African-Americans and other races.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
16
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1017-24
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10379964-African Americans,
pubmed-meshheading:10379964-Age Distribution,
pubmed-meshheading:10379964-Aged,
pubmed-meshheading:10379964-Aged, 80 and over,
pubmed-meshheading:10379964-European Continental Ancestry Group,
pubmed-meshheading:10379964-Humans,
pubmed-meshheading:10379964-Incidence,
pubmed-meshheading:10379964-Male,
pubmed-meshheading:10379964-Mass Screening,
pubmed-meshheading:10379964-Middle Aged,
pubmed-meshheading:10379964-Mortality,
pubmed-meshheading:10379964-Neoplasm Staging,
pubmed-meshheading:10379964-Population Surveillance,
pubmed-meshheading:10379964-Prostate-Specific Antigen,
pubmed-meshheading:10379964-Prostatic Neoplasms,
pubmed-meshheading:10379964-SEER Program,
pubmed-meshheading:10379964-Survival Rate,
pubmed-meshheading:10379964-United States
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.
|
|
pubmed:affiliation |
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892, USA. bh43a@nih.gov
|
|
pubmed:publicationType |
Journal Article
|
